Skip to Content for 2000 Annual Report Menu for 2000 Annual Report About Us Menu Research Menu Development Menu Medicines Menu Investors Menu Media Menu Careers Menu
Banner Image

2000 Annual Report

(dollars in millions, except per share data)

 
% Change from Preceding Year(3)
 
2000
1999
 
Years ended
December 31
Actual
Pro Forma
(1)
Actual(2)
Pro Forma(1)
1998
00/99
99/98
 
 
 
 
 
Total revenues
$ 1,736.4
$ 1,727.7
$ 1,401.0
$ 1,401.0
$ 1,150.9
23%
22%
 
 
 
 
 
Product sales
1,278.3
1,278.3
1,039.1
1,039.1
717.8
23
45
 
 
 
 
 
Cost of sales
364.9
272.1
285.6
192.2
138.6
42
39
 
 
 
 
 
Research and development (R&D) expenses
489.9
489.9
367.3
367.3
396.2
33
(7)
 
 
 
 
 
Marketing, general and administrative expenses
497.0
497.0
467.9
467.9
358.9
6
30
 
 
 
 
 
Special charges(4)
-
-
1,437.7
-
-
-
-
 
 
 
 
 
Recurring charges related to redemption(5)
375.3
-
197.7
-
-
-
-
 
 
 
 
 
Cumulative effect of accounting change, net of tax(6)
(57.8)
-
-
-
-
-
-
 
 
 
 
 
Net income (loss)
(74.2)
319.8
(1,157.5)
246.7
181.9
30
36
 
 
 
 
 
Diluted earnings (loss) per share(7)
(0.14)
0.60
(2.26)
0.47
0.35
28
34
 
 
 
 
 
R&D expense as a % of revenues
-
28%
-
26%
34%
-
-
 
 
 
 
 
Net income as a % of revenues
-
19%
-
18%
16%
-
-
 
 
 
 
 
Shares used to compute diluted earnings (loss) per share (millions)(7)
522.2
536.1
512.9
529.5
519.5
1
2
 
 
 
 
 
Actual shares at year-end (millions)(7)
525.5
525.5
516.2
516.2
508.5
2
2
 
 
 
 
 
Stock price at year-end(7)
$ 81.50
-
$ 67.25
-
$ 19.93
21
237
 
 
 
 
 
No cash dividends were paid.
 
 
 
 
 
 
 
 
 
 
 
 
Cash, short-term investments and long-term marketable securities
$ 2,459.4
-
$ 1,957.4
-
$ 1,604.6
26
22
 
 
 
 
 
Property, plant and equipment, net
752.9
-
730.1
-
700.2
3
4
 
 
 
 
 
Total assets
6,711.8
-
6,534.8
-
2,855.4
3
219
 
 
 
 
 
Total stockholders' equity
5,674.2
-
5,269.9
-
2,343.8
8
215
 
 
 
 
 
Capital expenditures
112.7
-
95.0
-
88.1
19
8
 
 
 
 
 
Number of employees
4,459
-
3,883
-
3,389
15
15

 

REVENUES(8)
Revenues
  
DILUTED EARNINGS PER SHARE(8)
Diluted Earnings
 
NET INCOME AS A PERCENT OF REVENUES(8)
Net Income

(1) Pro Forma amounts exclude the special charges in 1999 related to the Redemption and legal settlements, recurring charges related to the Redemption in 2000 and 1999, costs in 2000 and 1999 related to the sale of inventory that was written up at the Redemption, and their related tax effects. In addition, Pro Forma excludes the cumulative effect of a change in accounting principle, net of tax, in 2000. See the "Special Charges," "Recurring Charges Related to Redemption," "Cost of Sales," "Income Tax," and "Staff Accounting Bulletin No. 101" discussions in the Financial Review section of this annual report for further information on these charges. (2) Actual 1999 results include the combined New Basis and Old Basis presentation from the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows. In addition, we corrected the accounting related to the write up of the valuation allowance pertaining to unrealized gains on certain marketable securities. Refer to "Basis of Presentation and Restatement" in the Notes to Consolidated Financial Statements. (3) Percent change was calculated based on Pro Forma amounts and shares where applicable. (4) Amount includes $1,207.7 million related to the Redemption of our Special Common Stock and $230.0 million related to legal settlements. (5) Amounts primarily relate to the amortization of goodwill and other intangible assets due to the Redemption of our Special Common Stock. (6) We adopted the Securities and Exchange Commission's Staff Accounting Bulletin No. 101 on revenue recognition effective January 1, 2000, and recorded a cumulative effect of a change in accounting principle, net of tax. (7) All share, price per share and per share amounts of Common Stock and Special Common Stock reflect the two-for-one splits of our Common Stock that were effected in October 2000 and November 1999. (8) Graphs are based on Pro Forma amounts.